FibromyalgiaPhase 3NCT00333866
Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.
A Phase 3 study testing pregabalin in people with Fibromyalgia, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 74 sites in 16 countries.
Trial summary
This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fibromyalgia
- What is being tested?
- pregabalin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 747 participants
- Where
- 74 sitesin 16 countries
- Study dates
- Jul 2006to Nov 2007
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ACR criteria for fibromyalgia
- A score of more or equal to 40 mm on the Pain Visual Analog Scale (VAS) and a an average score more or equal to 4 on 4 daily pain diaries
Who cannot join
- Patients with other severe pain conditions
- Patients with severe depression
- Patients taking excluded medications
Trial locations and contacts
74 sites in 16 countries.
74 sites in 16 countries
Canada12 sites
Pfizer Investigational Site
Bathurst, New Brunswick, E2A 4X7
Pfizer Investigational Site
Drummondville, Quebec, J2B 7T1
Pfizer Investigational Site
Hawkesbury, Ontario, K6A 1A1
Pfizer Investigational Site
Kelowna, British Columbia, V1Y 2H4
Pfizer Investigational Site
Montreal, Quebec, H3T 1E2
Pfizer Investigational Site
Pointe-Claire, Quebec, H9R 3J1
Pfizer Investigational Site
Québec, Quebec, G1V 3M7
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 1Z1
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 5N4
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, A1B 3E1
Pfizer Investigational Site
Toronto, Ontario, M3K 2A7
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9
Germany6 sites
Pfizer Investigational Site
Bad Säckingen, 79713
Pfizer Investigational Site
Berlin, 10117
Pfizer Investigational Site
Berlin, 14109
Pfizer Investigational Site
Bonn, 53105
Pfizer Investigational Site
Mannheim, 68161
Pfizer Investigational Site
München, 80336
Italy6 sites
Pfizer Investigational Site
Bari, 79124
Pfizer Investigational Site
Benevento, 82100
Pfizer Investigational Site
Bologna, 40138
Pfizer Investigational Site
Chieti Scalo, 66013
Pfizer Investigational Site
Perugia, 06100
Pfizer Investigational Site
Pisa
France5 sites
Pfizer Investigational Site
Clermont-Ferrand, 63003
Pfizer Investigational Site
Lille, Cedex, 59037
Pfizer Investigational Site
Montpellier, Cedex 5, 34295
Pfizer Investigational Site
Paris, 75181
Pfizer Investigational Site
Saint-Etienne, 42055
Netherlands5 sites
Pfizer Investigational Site
Alkmaar, 1815 JD
Pfizer Investigational Site
Den Helder, 1782 GZ
Pfizer Investigational Site
Leeuwarden, 8934 AD
Pfizer Investigational Site
Rotterdam, 3015 GD
Pfizer Investigational Site
Zwolle, 8011 JW
United Kingdom5 sites
Pfizer Investigational Site
Greenock, Renfrewshire, PA16 0XN
Pfizer Investigational Site
London, WC1X 8LD
Pfizer Investigational Site
Manchester, Greater Manchester, M6 8HD
Pfizer Investigational Site
North Shields, Tyne and Wear, NE29 8NH
Pfizer Investigational Site
Poole, BH12 2JB
Australia4 sites
Pfizer Investigational Site
Clayton, Victoria, 3168
Pfizer Investigational Site
Fitzroy, Victoria, 3065
Pfizer Investigational Site
Maroochydore, Queensland, 4558
Pfizer Investigational Site
Warrawong, New South Wales, 2502
India4 sites
Pfizer Investigational Site
Indore, Madhya Pradesh, 452001
Pfizer Investigational Site
Lucknow, Uttar Pradesh, 226 014
Pfizer Investigational Site
Ludhiana, Punjab, 141 001
Pfizer Investigational Site
Ludhiana, Punjab, 141 008
Mexico4 sites
Pfizer Investigational Site
León, Guanajuato, 37520
Pfizer Investigational Site
México, D. F., 14080
Pfizer Investigational Site
Monterrey, Nuevo León, 64020
Pfizer Investigational Site
San Luis Potosí City, 78240
Portugal4 sites
Pfizer Investigational Site
Lisbon, 1050-054
Pfizer Investigational Site
Lisbon, 1249-075
Pfizer Investigational Site
Lisbon, 1349-019
Pfizer Investigational Site
Lisbon, 1700-360
Spain4 sites
Pfizer Investigational Site
Barcelona, 08024
Pfizer Investigational Site
Barcelona, 08035
Pfizer Investigational Site
Córdoba, 14004
Pfizer Investigational Site
Guadalajara, 19002
Sweden4 sites
Pfizer Investigational Site
Linköping, 581 85
Pfizer Investigational Site
Mölndal, 431 37
Pfizer Investigational Site
Örebro, 701 85
Pfizer Investigational Site
Stockholm, SE-112 81
South Korea3 sites
Pfizer Investigational Site
Seoul, 133-792
Pfizer Investigational Site
Seoul, 143-914
Pfizer Investigational Site
Suwon, Kyeongki-do, 442-712
Switzerland3 sites
Pfizer Investigational Site
Lausanne, 1011
Pfizer Investigational Site
Zurich, 8063
Pfizer Investigational Site
Zurich, 8091
Venezuela3 sites
Pfizer Investigational Site
Caracas, Distrito Federal, 1010
Pfizer Investigational Site
Caracas, Distrito Federal, 1060
Pfizer Investigational Site
Caracas, Miranda, 1081
Denmark2 sites
Pfizer Investigational Site
Frederiksberg, 2000
Pfizer Investigational Site
Svendborg, 5700
About this study
Official title: A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.
- Conditions
- Fibromyalgia
- Being tested
- pregabalin, placebo
- Medical subject headings
- Fibromyalgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pregabalinDrug
600mg/day
pregabalinDrug
450mg/day
pregabalinDrug
300mg/day
placeboDrug
placebo
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: pregabalin |
| 2 | Experimental | Not described Receives: Drug: pregabalin |
| 3 | Experimental | Not described Receives: Drug: pregabalin |
| 4 | Placebo comparator | Not described Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14)
Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication.
Measured: Baseline, Week 14
Patient Global Impression of Change (PGIC)
Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse).
Measured: Week 14
Secondary outcomes (11)
Change From Baseline in Mean Sleep Quality Score at Endpoint (Up to Week 14)
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The endpoint (up to week 14) mean quality of sleep score was based on Least Squares (LS) Means using ANCOVA, with treatment group and center in the model and the baseline mean sleep score used as the covariate. Final weekly (endpoint) mean sleep quality score is defined as the mean sleep quality score from the last 7 sleep diary entries in the study while the participant was on study medication.
Measured: Baseline, Week 14
Change From Baseline in Weekly Mean Sleep Quality Score
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The weekly mean quality of sleep score was based on LS Means using mixed model repeated measures ANCOVA, with treatment, center, week, and treatment-by-week interaction in the model and the baseline mean sleep score used as the covariate. Weekly mean sleep quality score is defined as the mean of the last 7 daily sleep diary entries.
Measured: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
Percentage of Participants With Optimal Sleep Assessed Using MOS-SS
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more disturbance.
Measured: Baseline, Week 14
Change From Baseline in Medical Outcomes Study (MOS): Sub-scales at Week 14
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.
Measured: Baseline, Week 14
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Subscale Scores at Week 14
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment.
Measured: Baseline, Week 14
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Scores at Week 14
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment.
Measured: Baseline, Week 14
Change From Baseline in Short Form-36 (SF-36) Health Survey at Week 14
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.
Measured: Baseline, Week 14
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) at Week 14
MAF is a 16-item self-administered questionnaire that yields a Global Fatigue Index (GFI), measures 4 dimensions of fatigue: degree and severity, amount of distress it causes, its timing and degree to which fatigue interferes with activities of daily living. Only 15 items are used to calculate the GFI. GFI score range from 1 (no fatigue) to 50 (severe fatigue).
Measured: Baseline, Week 14
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 14
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Measured: Baseline, Week 14
Change From Baseline in Pain Visual Analogue Scale (VAS) Scores at Week 14
Pain visual analog scale (VAS): Participants assessed the severity of their pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (worst possible pain), measurement on a scale corresponds to the magnitude of their pain.
Measured: Baseline, Week 14
Total Daily Acetaminophen Dose
Acetaminophen (up to 4 gram/day as needed for pain relief) was an allowable concomitant medication as a rescue therapy. The total daily acetaminophen dose taken during double-blind treatment was calculated for each participant as: (total acetaminophen dose during the study) divided by (total number of study days).
Measured: Week 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2006 (estimated)
- Study startJul 2006
- Primary completionNov 2007
- Study completionNov 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 747 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00333866
- Sponsor's protocol ID
- A0081100
- Status last verified
- Mar 2009
- First submitted
- 2 Jun 2006
- Last updated
- 11 Feb 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27.
PubMed 26694975Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B; A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011 Dec;38(12):2643-52. doi: 10.3899/jrheum.110569. Epub 2011 Oct 1.
PubMed 21965636Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125.
PubMed 21639874Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin Pharmacother. 2010 Dec;11(17):2805-12. doi: 10.1517/14656566.2010.525217. Epub 2010 Nov 2.
PubMed 21039311Bennett RM, Russell J, Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A. Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord. 2010 Jun 28;11:134. doi: 10.1186/1471-2474-11-134.
PubMed 20584327
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
- ClinicalTrials.gov ID
- NCT00333866
- Acronym / sponsor ID
- A0081100
- Conditions
- Fibromyalgia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 747 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Jul 2006
- Primary completion
- Nov 2007 (actual)
- Study completion
- Nov 2007 (actual)
- First posted
- 6 Jun 2006 (estimated)
- Results
- Posted 13 May 2009
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: pregabalin |
| 2 | Experimental | Drug: pregabalin |
| 3 | Experimental | Drug: pregabalin |
| 4 | Placebo comparator | Drug: placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- ACR criteria for fibromyalgia
- A score of more or equal to 40 mm on the Pain Visual Analog Scale (VAS) and a an average score more or equal to 4 on 4 daily pain diaries
Key exclusion criteria (3 listed)
- Patients with other severe pain conditions
- Patients with severe depression
- Patients taking excluded medications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pregabalin600mg/day | Drug | 1 |
| pregabalin450mg/day | Drug | 2 |
| pregabalin300mg/day | Drug | 3 |
| placeboplacebo | Drug | 4 |
Primary outcome
Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14)
Time frame: Baseline, Week 14
Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication.
Patient Global Impression of Change (PGIC)
Time frame: Week 14
Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse).
11 secondary outcomes
Change From Baseline in Mean Sleep Quality Score at Endpoint (Up to Week 14)
Time frame: Baseline, Week 14
Change From Baseline in Weekly Mean Sleep Quality Score
Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
Percentage of Participants With Optimal Sleep Assessed Using MOS-SS
Time frame: Baseline, Week 14
Change From Baseline in Medical Outcomes Study (MOS): Sub-scales at Week 14
Time frame: Baseline, Week 14
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Subscale Scores at Week 14
Time frame: Baseline, Week 14
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Scores at Week 14
Time frame: Baseline, Week 14
Change From Baseline in Short Form-36 (SF-36) Health Survey at Week 14
Time frame: Baseline, Week 14
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) at Week 14
Time frame: Baseline, Week 14
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 14
Time frame: Baseline, Week 14
Change From Baseline in Pain Visual Analogue Scale (VAS) Scores at Week 14
Time frame: Baseline, Week 14
Total Daily Acetaminophen Dose
Time frame: Week 14
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26694975Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27.
- Derived from this study: PubMed 21965636Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B; A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011 Dec;38(12):2643-52. doi: 10.3899/jrheum.110569. Epub 2011 Oct 1.
- Derived from this study: PubMed 21639874Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125.
- Derived from this study: PubMed 21039311Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin Pharmacother. 2010 Dec;11(17):2805-12. doi: 10.1517/14656566.2010.525217. Epub 2010 Nov 2.
- Derived from this study: PubMed 20584327Bennett RM, Russell J, Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A. Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord. 2010 Jun 28;11:134. doi: 10.1186/1471-2474-11-134.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Fibromyalgia
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Recruiting
Auricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia
Fibromyalgia Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
74 sites in 16 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing pregabalin in people with Fibromyalgia, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 74 sites in 16 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 74 sites in Canada, Germany, Italy, France, Netherlands and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 May 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14) (time frame: Baseline, Week 14). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00333866, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2021.